AMR Action Fund
Impact investorBoston · Seed–Series C · 14 people tracked
Investment thesis
The AMR Action Fund focuses on combating antimicrobial resistance (AMR) by investing in biotech companies developing treatments for patients suffering from life-threatening antimicrobial-resistant infections, with a stated goal of enabling 2 to 4 novel antibiotics by 2030. Beyond capital, the fund works to build partnerships that create a sustainable innovation ecosystem so new treatments continue to evolve alongside the AMR threat, and it advocates for market reforms and policy solutions that change how society values these lifesaving drugs.
Source: firm website, verified Aug 25, 2026.
Team · 14 people
from the firm's website & curated & public directories
What they invest in
from 16 of 20 portfolio companiesBiotech ×16Healthtech ×10Medical Devices ×6AI & Machine Learning ×3Deep Tech ×3Digital Health ×3Cybersecurity ×1Defense Tech ×1
HQs:United States×10Switzerland×1Spain×1United Kingdom×1
Investments · 20 tracked
founders shown can be your intro pathBy year:2026 · 12024 · 12023 · 32022 · 12020 · 12016 · 18 dated
BiomX builds a portfolio of defense and security companies through subsidiaries, partnerships, and acquisitions, focusing on detection systems, aerial technologies, and infrastructure security.
AI & Machine LearningBiotechCybersecurityDeep TechDefense TechHardware
Jonathan Solomon(Chief Executive Officer)Merav Bassan(Chief Development Officer)Marina Wolfson(Chief Financial Officer)Jesse Goodman(Director)Alan Moses(Director)Jonathan Leff(Director)
Co-investorsBaruch Future VenturesNSG VenturesOrbiMed8VC
Antabio is a clinical-stage biopharmaceutical company developing novel antibacterial treatments for drug-resistant, Gram-negative bacterial infections identified as critical priorities by the WHO and CDC, with a focus on life-threatening hospital-acquired infections.
BiotechHealthtech
Marc Lemonnier(Chief Executive Officer)Rienk Pypstra(Chief Medical Officer)Gordon Waldron(Chief Financial Officer)Magdalena Zalacain(Chief Scientific Officer)
Co-investorsBNP Paribas Développement
Centauri Therapeutics develops the Alphamer platform, a proprietary antibody recruiting molecule technology designed to redirect the immune system against disease targets.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsNCL Technology Ventures Ltd.
Pattern develops rapid antibiotic susceptibility and infection diagnostics using single-cell microbiology, which reads the metabolic patterns of individual bacterial cells to deliver ID/AST results in hours without culture steps.
BiotechHealthtechMedical DevicesAustin, US
Nick Arab(Founder & CTO)Ross Johnson(Co-founder & Chief Engineer)Carey-Ann Burnham(Chief Executive Officer)Travis Davies(SVP, Operations)Kyle Fieleke(SVP, Corporate Development & Finance)David Bussian(SVP, Clinical, Regulatory & Assay Development)
Co-investorsIllumina Ventures
BiotechArlington, US
Jon Weidanz(Director and President)Debra Weidanz(CEO and Director)
Board seatMartin Heidecker· per SEC Form D · $1.7M raise · filed Sep 2016
BiotechGaithersburg, US
Gregory L. Merril(Executive Officer, Director, Promoter)Carl R. Merril(Executive Officer, Director)
BoardJonathan Leff(Director)inEvan Loh(Director)Jana Jensen(Director)Raymond L. Martz(Director)
Board seatMartin Heidecker· per SEC Form D · $30M raise · filed Jun 2023
Co-investorsSofinnova Ventures
Clinical-stage biotech developing next-generation polyene antifungals for life-threatening invasive fungal infections.
BiotechNew York, US
Kieren Marr(Executive Officer, Director)
BoardJim Flynn(Director)Jonathan Leff(Director)
Board seatMartin Heidecker· per SEC Form D
Co-investorsIllinois VenturesDeerfield Management Company
Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Travis Wager(Co-founder, President and CSO)Hualin Simon Xi(Executive Officer, Director)Zhiping Weng(Co-founder)Simon Xi(Co-founder and CEO)Jackie Walling(CMO)Debasish Roychowdhury(Director)
Board seatMartin Heidecker· per SEC Form D · $38M raise · filed Mar 2021
Co-investorsDelos CapitalVivo CapitalBoehringer Ingelheim Venture FundKorea Investment PartnersLilly Asia VenturesMatrix Partners China
Vedanta Biosciences is a clinical-stage biotech developing Live Biotherapeutic Products (LBP) based on defined consortia of bacteria to treat serious gastrointestinal diseases, with an initial focus on preventing recurrent Clostridium difficile infection.
BiotechHealthtechCambridge, US
Bernat Olle(Executive Officer, Director)inDaniel Couto(Executive Officer)inMark Mullikin(Executive Officer)inJeffrey Silber(Executive Officer)inChristopher Viehbacher(Director)
BoardJohn LaMattina(Director)
Board seatMartin Heidecker· per SEC Form D
Co-investorsK2 HealthVenturesSalica InvestmentsSeventure PartnersBNP ParibasBNP Paribas Asset Management EuropeTullis
Developing ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor combination for complicated urinary tract infections.
Malvern, US
Board seatMartin Heidecker· per SEC Form D
Co-investorsBioAdvanceForesite Capital
BioVersys is a clinical-stage biotech company focused on developing antimicrobial therapies to address unmet medical needs in infectious diseases, including tuberculosis and hospital-acquired infections.
BiotechDeep TechHealthtechMedical DevicesBasel, CH
Dr. Marc Gitzinger(Chief Executive Officer & Founder)Marc Gitzinger(Chief Executive Officer & Co-founder)
Co-investorsStartAngels Network
F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsAdvent Life SciencesAisling CapitalAstellas Venture Management LLCBrace PharmaSofinnova PartnersSunstone Capital+3 more
Developing a diagnostics platform using single-cell analysis and machine learning to rapidly identify bacterial pathogens and determine antibiotic susceptibility.
Co-investorsIllumina Ventures
BiotechAustin, US
Carey-Ann Burnham(Executive Officer, Director)Nicolas Arab(Executive Officer, Director)Johnson Ross(Executive Officer)Bryan Gammon(Director)Oscar Marx(Director)
BoardJunjun Gao(Director)
Co-investorsIllumina InnovationIllumina Ventures
Peptilogics is a clinical-stage surgical therapeutics company developing zaloganan (PLG0206), a novel anti-biofilm drug to treat and prevent medical device-related infections such as prosthetic joint infections.
BiotechHealthtechMedical DevicesPittsburg, US
Jonathan Steckbeck(Executive Officer, Director)in
BoardStephan Dietrich(Director)in
Co-investorsAAF Management Ltd.Alpha Wave GlobalMountain State CapitalNarya CapitalRiverfront Ventures, LLCTachyon Ventures+5 more
Telum Therapeutics develops antimicrobial drugs using synthetic biology and AI-driven machine learning, specializing in engineered lytic proteins to address multidrug-resistant infections.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesNoáin, ES
Subhendu Basu(Chief Executive Officer)inRoberto Díez(Chief Operating Officer)inDiana Gutiérrez(Chief Scientific Officer)in
Co-investorsInvivo Capital Partners
BiotechRedwood City, US
Larry Kauvar(Chief Science Officer)Stefan Ryser(President and Chief Executive Officer)Geoff Dillon(Chief Business Officer)Elisabeth Whitney(Chief Operating Officer)Nora Mende(Chief Financial Officer)
PartnerJunjun Gao· ledHenry Skinner· quoted
Co-investorsEaston CapitalNew Science Ventures
Trellis Bioscience develops human monoclonal antibody therapeutics targeting bacterial, viral, and cancer indications.
BiotechHealthtech
Co-investorsNew Science Ventures
Obtained U.S.
Co-investors3B Future Health Fund
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 2
IPOs and acquisitions across the tracked portfolioBiomXNYSE: PHGEUtility Therapeuticsacq. by Alembic Pharmaceuticals
Portfolio news
latest coverage across their companiesBiomX · stocktitan.net · Aug 14, 2026
Vedanta Biosciences · allsci.com · Aug 10, 2026
Trellis Bioscience · beckersspine.com · Jul 20, 2026
Pattern · investing.com · Jul 14, 2026
F2G · endpoints.news · Jan 23, 2026
Peptilogics · nasdaqprivatemarket.com · Oct 28, 2025
Frequently asked questions
- How many investments has AMR Action Fund made?
- AMR Action Fund has 15 tracked investments, 1 of which have exited via acquisition or IPO.
- What stage does AMR Action Fund invest at?
- AMR Action Fund invests at the Seed, Series A, Series B, Series C stages.
- What sectors does AMR Action Fund focus on?
- AMR Action Fund focuses on Biotech, Healthtech, Impact & Social Good, Medical Devices.
- Where is AMR Action Fund located?
- AMR Action Fund is headquartered in Boston, US.
- Who does AMR Action Fund co-invest with?
- AMR Action Fund most often shares deals with Illumina Ventures, Aisling Capital, Foresite Capital, among 26 tracked co-investors.
Images
Similar investors
Innovestor is a Finnish investment manager active in venture capital, real estate, and energy storage, and also provides corporate venturing services.
Cancer Fund is an early-stage oncology venture capital and venture-giving organization that funds diagnostics, therapeutics, and other cancer-targeting innovations, offering both charitable donation and accredited-investor pathways.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Forbion is a global venture capital firm focused on advancing biotech innovations and sustainable solutions aimed at improving human and planetary health.
MDI Ventures is the corporate venture capital arm of Telkom Indonesia, investing in and building synergies between technology startups and Indonesian enterprises. It manages a multi-fund platform (including Centauri Fund, Arise, and sector-specific funds) with a portfolio of 80+ companies.